BR112014024964A8 - formulação compósita compreendendo comprimido esferoidal de multi-unidade (must) encapsulado em cápsula dura e método para sua preparação - Google Patents

formulação compósita compreendendo comprimido esferoidal de multi-unidade (must) encapsulado em cápsula dura e método para sua preparação

Info

Publication number
BR112014024964A8
BR112014024964A8 BR112014024964A BR112014024964A BR112014024964A8 BR 112014024964 A8 BR112014024964 A8 BR 112014024964A8 BR 112014024964 A BR112014024964 A BR 112014024964A BR 112014024964 A BR112014024964 A BR 112014024964A BR 112014024964 A8 BR112014024964 A8 BR 112014024964A8
Authority
BR
Brazil
Prior art keywords
capsule
unit
hard capsule
composite formulation
formulation
Prior art date
Application number
BR112014024964A
Other languages
English (en)
Other versions
BR112014024964A2 (pt
BR112014024964B1 (pt
Inventor
Kyeong Soo Kim
Dong Ho Kim
Taek Kwan Kwon
Yong Il Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49327885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014024964(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR112014024964A2 publication Critical patent/BR112014024964A2/pt
Publication of BR112014024964A8 publication Critical patent/BR112014024964A8/pt
Publication of BR112014024964B1 publication Critical patent/BR112014024964B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

formulação compósita compreendendo comprimido esferoidal de multi-unidade (must) encapsulado em cápsula dura e método para preparação. a presente invenção refere-se a uma formulação compósita compreendendo comprimidos esferoidais de multi-unidades (musts) encapsulados em uma cápsula dura e a um método para preparação da mesma. a formulação compósita de cápsula dura da invenção pode efetivamente carregar os must's no espaço limitado da cápsula,o que permite o carregamento de uma dose elevada de ingredientes farmaceuticamente ativos diferentes, em uma cápsula com um tamanho relativamente pequeno, para desse modo, aumentar a produtividade e torná-la facilmente administrada a pacientes. além disso, a cápsula tem uma boa taxa de dissolução porque os ingredientes farmaceuticamente ativos contidos na cápsula são separados uns dos outros; por conseguinte, as taxas de dissolução dos ingredientes são menos afetadas por outras. também pode ser possível maximizar os efeitos terapêuticos dos ingredientes farmaceuticamente ativos, uma vez que a formulação compósita tem boa estabilidade.
BR112014024964-4A 2012-04-13 2013-04-12 Formulação compósita compreendendo comprimido esferoidal de multi-unidade (must) encapsulado em cápsula dura e método para sua preparação BR112014024964B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2012-0038594 2012-04-13
KR1020120038594A KR101378973B1 (ko) 2012-04-13 2012-04-13 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
PCT/KR2013/003099 WO2013154390A1 (en) 2012-04-13 2013-04-12 Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same

Publications (3)

Publication Number Publication Date
BR112014024964A2 BR112014024964A2 (pt) 2017-06-20
BR112014024964A8 true BR112014024964A8 (pt) 2021-06-15
BR112014024964B1 BR112014024964B1 (pt) 2022-03-15

Family

ID=49327885

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014024964-4A BR112014024964B1 (pt) 2012-04-13 2013-04-12 Formulação compósita compreendendo comprimido esferoidal de multi-unidade (must) encapsulado em cápsula dura e método para sua preparação

Country Status (22)

Country Link
US (1) US20150098992A1 (pt)
EP (1) EP2836207B1 (pt)
JP (1) JP6129295B2 (pt)
KR (1) KR101378973B1 (pt)
CN (2) CN110051642B (pt)
BR (1) BR112014024964B1 (pt)
CL (1) CL2014002717A1 (pt)
CO (1) CO7131367A2 (pt)
ES (1) ES2778864T3 (pt)
HK (1) HK1204959A1 (pt)
MX (1) MX354328B (pt)
MY (1) MY171703A (pt)
PE (1) PE20142035A1 (pt)
PH (1) PH12014502271B1 (pt)
PL (1) PL2836207T3 (pt)
PT (1) PT2836207T (pt)
RU (1) RU2014145557A (pt)
SG (1) SG11201406298RA (pt)
TW (1) TWI544936B (pt)
UA (1) UA116102C2 (pt)
WO (1) WO2013154390A1 (pt)
ZA (1) ZA201408285B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
CA2965237C (en) * 2014-10-21 2023-11-21 Reckitt Benckiser Llc Pharmaceutical capsule containing at least two tablets
KR20170003459A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
BE1023011B1 (nl) * 2015-08-05 2016-11-04 Nordic Specialty Pharma Bvba Acetylsalicylzuur tablet met onmiddellijke afgifte
WO2017062997A1 (en) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation
KR101625344B1 (ko) * 2015-12-21 2016-06-08 주식회사 유영제약 세레콕시브 및 둘록세틴을 함유하는 약제학적 조성물
EP3222279B1 (en) 2016-03-21 2021-11-17 Invest Bielany Spolka z ograniczona odpowiedzialnoscia Oral pharmaceutical formulation of montelukast and levocetirizine and method for its production
KR101920996B1 (ko) * 2017-04-26 2018-11-22 알보젠코리아 주식회사 HMG-CoA 환원효소 저해제 및 칼슘채널 차단제를 포함하는 복합제제
US20200368219A1 (en) * 2017-09-28 2020-11-26 Hanmi Pharm. Co., Ltd. Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition
KR102026982B1 (ko) * 2018-02-02 2019-09-30 주식회사 씨티씨바이오 캡슐 충진 장치
MX2021011795A (es) * 2019-04-02 2022-01-18 Hanmi Pharm Ind Co Ltd Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble.
KR20210052281A (ko) * 2019-10-29 2021-05-10 신에쓰 가가꾸 고교 가부시끼가이샤 캡슐 충전용 조성물 및 이것을 사용한 캡슐 제제의 제조 방법 그리고 캡슐 제제
US20210275531A1 (en) * 2020-03-04 2021-09-09 VK Research Associates Inc Phosphodiesterase-5 inhibitor combinations, methods of making, and methods of use thereof
KR20230005229A (ko) 2020-04-17 2023-01-09 허니브레인즈, 엘엘씨 신경정신계 장애를 치료하기 위한 조성물 및 방법
EP4085903A1 (de) * 2021-05-07 2022-11-09 Midas Pharma GmbH Minitablette enthaltend losartan für pädiatrische anwendungen
CA3229117A1 (en) * 2021-08-19 2023-02-23 Dorit MIMROD Method of treating parkinson's disease
KR20240045586A (ko) 2022-09-30 2024-04-08 주식회사 제뉴원사이언스 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 포함하는 안정성이 향상된 이층정 정제 및 그의 제조방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4773907A (en) * 1982-12-20 1988-09-27 Alza Corporation Primary delivery system comprising secondary dosage form
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
GB9711962D0 (en) * 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
JP2000128779A (ja) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc 薬物放出制御型製剤
DE19901683B4 (de) * 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
IL147826A0 (en) * 1999-07-30 2002-08-14 Smithkline Beecham Plc Multi-component pharmaceutical dosage form
US20060257482A1 (en) * 2002-06-07 2006-11-16 Patrik Kumar Modified release, multiple unit drug delivery systems
DE602004007315D1 (de) 2003-03-03 2007-08-16 Personnes A Responsibilite Lim Stabilisierte pharmazeutische Zusammensetzung enthaltend einen NSAID und einen Prostaglandin
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
US9233075B2 (en) * 2005-08-09 2016-01-12 Metacure Limited Satiety
KR100795419B1 (ko) * 2006-01-03 2008-01-17 (주)네오메딕스 암로디핀 및 아스피린을 함유하는 약학 제제
CA2662542A1 (en) * 2006-09-12 2008-03-20 Glaxo Group Limited Pharmaceutical composition comprising a plurality of mini-tablets comprising a factor xa inhibitor
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
WO2008132712A2 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Combination pharmaceutical compositions
KR100949273B1 (ko) * 2008-02-22 2010-03-25 한올제약주식회사 복합제제
KR20090091084A (ko) * 2008-02-22 2009-08-26 한올제약주식회사 방출성이 제어된 약제학적 제제
US8753680B2 (en) * 2008-03-28 2014-06-17 Ferrer Internacional S.A. Capsule for the prevention of cardiovascular diseases
TR201005325A2 (tr) * 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제

Also Published As

Publication number Publication date
US20150098992A1 (en) 2015-04-09
TW201345568A (zh) 2013-11-16
JP2015517998A (ja) 2015-06-25
ES2778864T3 (es) 2020-08-12
RU2014145557A (ru) 2016-06-10
PH12014502271A1 (en) 2014-12-10
MY171703A (en) 2019-10-23
HK1204959A1 (en) 2015-12-11
MX2014012144A (es) 2014-12-05
WO2013154390A1 (en) 2013-10-17
BR112014024964A2 (pt) 2017-06-20
EP2836207B1 (en) 2020-02-19
UA116102C2 (uk) 2018-02-12
CN104220050A (zh) 2014-12-17
ZA201408285B (en) 2016-09-28
PE20142035A1 (es) 2014-12-24
EP2836207A4 (en) 2015-08-19
TWI544936B (zh) 2016-08-11
PT2836207T (pt) 2020-03-26
SG11201406298RA (en) 2014-11-27
EP2836207A1 (en) 2015-02-18
CL2014002717A1 (es) 2015-01-09
KR20130115864A (ko) 2013-10-22
PL2836207T3 (pl) 2020-07-27
MX354328B (es) 2018-02-27
JP6129295B2 (ja) 2017-05-17
CN110051642A (zh) 2019-07-26
BR112014024964B1 (pt) 2022-03-15
CN110051642B (zh) 2021-12-31
CO7131367A2 (es) 2014-12-01
KR101378973B1 (ko) 2014-03-28
PH12014502271B1 (en) 2014-12-10

Similar Documents

Publication Publication Date Title
BR112014024964A8 (pt) formulação compósita compreendendo comprimido esferoidal de multi-unidade (must) encapsulado em cápsula dura e método para sua preparação
Bonakdar et al. Coenzyme Q10
AU2014363599B2 (en) Orally disintegrating solid dosage unit containing an estetrol component
Anaeigoudari et al. Lipopolysaccharide-induced memory impairment in rats is preventable using 7-nitroindazole
WO2016042163A3 (en) Ophthalmic drug compositions
ECSP15039103A (es) Formulación de liberación sostenida de mosapride que proporciona efectos farmacológicos y clínicos con administración una vez al día
BR112015022896A2 (pt) drogas de alta penetração e suas composições para o tratamento de doenças de parkinson
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
WO2012125830A3 (en) Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control
Sun et al. Metabolic profiling of hypoxia/reoxygenation injury in H9c2 cells reveals the accumulation of phytosphingosine and the vital role of Dan-Shen in Xin-Ke-Shu
UA112352C2 (uk) Фармацевтична композиція для профілактики і лікування психічних, поведінкових, когнітивних розладів
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
BR112016002342A2 (pt) Microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
CN104706604A (zh) 一种吡仑帕奈冻干口崩片及其制备方法
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
MX2020001760A (es) Composicion farmaceutica que incluye un comprimido esferoide de multiples unidades que contiene esomeprazol y una sal farmaceuticamente aceptable esferoide de este, y metodo para preparar la composicion farmaceutica.
Ravera et al. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain
CN105147696A (zh) 联合使用盐酸二甲双胍和gdc0941的抗乳腺癌颗粒剂及制备方法
WO2015053910A3 (en) Pharmaceutical preparation of carbohydrates for therapeutic use
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite
RU2017129068A (ru) Способ лечения или профилактики атеротромботических явлений у пациентов с инфарктом миокарда в анамнезе
JP2018076312A (ja) アセトアミノフェン、イソプロピルアンチピリン及びショウガ由来成分を含有する医薬組成物
CN102727515A (zh) 一种治疗脚气的药物制剂

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/04/2013, OBSERVADAS AS CONDICOES LEGAIS.